Trial Profile

EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peanut allergy immunotherapy (Primary)
Indications Peanut hypersensitivity
Focus Adverse reactions; Therapeutic Use
Acronyms EPOPEX
Sponsors DBV Technologies

Most Recent Events

06 Jun 2025 Status changed from active, no longer recruiting to completed.
08 Jan 2025 According to a DBV Technologies media release, data from the study will be presented in poster presentations at the Eastern Food Allergy & Comorbidity Conference, which is being held January 9th through 12th, 2025, in Palm Beach, Florida.
08 Jan 2025 Results published in the DBV Technologies Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com